Parallels have been discussed to the cyst formation in LAM that might result from interactions between the estrogen signaling pathway and the mechanistic target of rapamycin (mTOR), in which both the tuberous sclerosis complex and FLCN are involved (18, 19). The gene discussed is FLCN; the disease is lymphangioleiomyomatosis.